Alterity Therapeutics (PRNAD) Income towards Parent Company (2009 - 2019)

Alterity Therapeutics (PRNAD) has reported Income towards Parent Company for 9 consecutive years, with $87328.6 the latest figure, recorded in Q4 2019.

• In Q4 2019, Income towards Parent Company fell 97.72% year-over-year to $87328.6; the TTM figure through Jun 2021 stood at $87328.6 (down 92.32% YoY), while the FY2025 annual figure was -$7.8 million, up 100.0% from the prior year.
• Income towards Parent Company came in at $87328.6 for Q4 2019 at Alterity Therapeutics, up from -$109.7 million in the prior quarter.
• The five-year high for Income towards Parent Company was $3.8 million in Q4 2018, with the low at -$109.7 million in Q2 2019.
• Average Income towards Parent Company over 4 years is -$54.8 million, with a median of -$55.5 million recorded in 2017.
• Across the five-year window, Income towards Parent Company surged 237.71% in 2018 and tumbled 97.72% in 2019, its largest moves.
• Year by year, Income towards Parent Company stood at -$2.7 million in 2016, then retreated by 1.55% to -$2.8 million in 2017, then soared by 237.71% to $3.8 million in 2018, then sank by 97.72% to $87328.6 in 2019.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $87328.6, -$109.7 million, and $3.8 million for Q4 2019, Q2 2019, and Q4 2018 respectively.